Merrimack Pharmaceuticals to Present Preclinical Data on Bispecific Antibody MM-111 in ErbB2-Positive Gastric Cancers

[at noodls] – CAMBRIDGE, Mass., Jan. 23, 2013 (GLOBE NEWSWIRE) — Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) announced today that preclinical data regarding the bispecific antibody MM-111 will be presented at the … more

View todays social media effects on MACK

View the latest stocks trending across Twitter. Click to view dashboard

See who Merrimack is hiring next, click here to view